Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine vs Bupivacaine plus Dexmedetomidine for Postoperative Pain in Abdominal Surgery
NCT06531603Phase 3Completed
- Sponsor
- Sahiwal Medical College
- Start
- Feb 2022
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine in postoperative pain, sponsored by Sahiwal Medical College. Primary endpoint: Duration of analgesia at 24 hours. Started Feb 2022; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06531603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06531603.